This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Regimens for Drug-Resistant Tuberculosis

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

A three-drug regimen has strong efficacy against highly drug-resistant tuberculosis, but it has high toxicity with linezolid at a dose of 1200 mg. A different dose and duration might improve safety and maintain efficacy. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account